Phase II trial of rituximab-CHOP (R-CHOP) [cyclophosphamide, doxorubicin, vincristine, and prednisone] plus GM-CSF [granulocyte macrophage colony stimulating factors] for previously untreated diffuse large cell lymphoma in the elderly.

Trial Profile

Phase II trial of rituximab-CHOP (R-CHOP) [cyclophosphamide, doxorubicin, vincristine, and prednisone] plus GM-CSF [granulocyte macrophage colony stimulating factors] for previously untreated diffuse large cell lymphoma in the elderly.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2010

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Granulocyte-macrophage colony-stimulating factors; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 10 Dec 2010 Status changed from active, no longer recruiting to completed
    • 12 May 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top